Hence, as the downstream activation of RhoA was observed to be relevant to the migration phenotype, we observed its effects in thyroid cancer cells treated with TSH with a GST-Rhotekin pulldown assay. This evidence concerns the gene RHOA and thyroid gland carcinoma.